Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: No in vivo effect of Fas ligand tumor counterattack

Clinical Cancer Research

Volumn 10, Issue 23, 2004, Pages 7911-7916

  Donskov, Frede ^a,b   Von Der Maase, Hans ^a   Marcussen, Niels ^a   Hamilton Dutoit, Stephen ^a   Madsen, Hans Henrik Torp ^a   Jensen, Jens Jorgen ^a   Hokland, Marianne ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD4 ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; CD8 ANTIGEN; FAS LIGAND; HISTAMINE; INTERFERON ALFANATIVE; INTERLEUKIN 2; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEEDLE BIOPSY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY; TUMOR CELL; TUMOR COUNTERATTACK;

ADULT; AGED; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; FAS LIGAND PROTEIN; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOTHERAPY; INTERLEUKIN-2; KIDNEY NEOPLASMS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; SURVIVAL RATE;

EID: 9744265752     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1111     Document Type: Article

References (39)

1. Griffith TS, Ferguson TA. The role of FasL-induced apoptosis in immune privilege. Immunol Today 1997;18:240-4.
2. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science (Wash D C) 1996;274:1363-6.
3. Andreola G, Rivoltini L, Castelli C, et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 2002;195:1303-6.
4. Saas P, Walker PR, Hahne M, et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Investig 1997;99:1173-8.
5. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075-82.
6. Bennett MW, O'Connell J, O'Sullivan GC et al. The Fas counter-attack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998;160:5669-75.
7. Niehans GA, Brunner T, Frizelle SP, et al. Human lung carcinomas express Fas ligand. Cancer Res 1997;57:1007-12.
8. Rabinowich H, Reichert TE, Kashii Y, et al. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J Clin Investig 1998;101:2579-88.
9. Gastman BR, Atarshi Y, Reichert TE, et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 1999;59:5356-64.
10. Ungefroren H, Voss M, Jansen M, et al. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res 1998;58:1741-9.
11. Chappell DB, Zaks TZ, Rosenberg SA, Restifo NP. Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res 1999; 59:59-62.
12. Favre-Felix N, Fromentin A, Hammann A, et al. Cutting edge: the tumor counterattack hypothesis revisited: colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway. J Immunol 2000;164:5023-7.
13. Restifo NP. Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med 2000;6:493-5.
14. Restifo NP. Countering the 'counterattack' hypothesis. Nat Med 2001;7:259.
15. Ragnarsson GB, Mikaelsdottir EK, Vidarsson H, et al. Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells. Br J Cancer 2000;83:1715-21.
16. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: cancer as a site of immune privilege. Immunol Today 1999;20:46-52.
17. Whiteside TL. Tumor-induced death of immune cells: its mechanisms and consequences. Semin Cancer Biol 2002;12:43-50.
18. Uzzo RG, Rayman P, Kolenko V, et al. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin Cancer Res 1999; 5:1219-29.
19. Peduto EL, Guillou L, Saraga E, et al. Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas. Int J Cancer 1999;81:772-8.
20. Olive C, Cheung C, Nicol D, Falk MC. Expression of apoptotic regulatory molecules in renal cell carcinoma: elevated expression of Fas ligand. Immunol Cell Biol 1999;77:11-8.
21. Gerharz CD, Ramp U, Dejosez M, et al. Resistance to CD95 (APO-1/Fas)-mediated apoptosis in human renal cell carcinomas: an important factor for evasion from negative growth control. Lab Investig 1999;79:1521-34.
22. Kim YS, Kim KH, Choi JA, et al. Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: correlation with the prognostic factors. Arch Pathol Lab Med 2000;124:687-93.
23. Leroy X, Wacrenier A, De la TA, et al. Immunohistochemical detection of Fas and Fas ligand in sarcomatoid renal cell carcinoma. APMIS 2001;109:469-73.
24. Koga F, Arai K, Kamai T, Abe H, Yoshida K. Fas labeling status does not correlate with apoptosis of renal cell carcinoma in vivo. Anticancer Res 2001;21:3193-7.
25. Sejima T, Isoyama T, Miyagawa I. Alteration of apoptotic regulatory molecules expression during carcinogenesis and tumor progression of renal cell carcinoma. Int J Urol 2003;10:476-84.
26. Donskov F, Bennedsgaard KM, Hokland M, et al. Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma. Cancer Immunol Immunother 2004;53:729-39.
27. Rubin JT, Elwood LJ, Rosenberg SA, Lotze MT. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res 1989;49:7086-92.
28. Donskov F, von der Maase H, Henriksson R, et al. Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II study. Ann Oncol 2002;13:441-9.
29. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-40.
30. Gundersen HJ, Bendtsen TF, Korbo L, et al. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS 1988;96:379-94.
31. Soubrane C, Mouawad R, Antoine EC, et al. A comparative study of Fas and Fas-ligand expression during melanoma progression. Br J Dermatol 2000;143:307-12.
32. Botti C, Buglioni S, Benevolo M, et al. Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy. Clin Cancer Res 2004;10:1360-5.
33. Munakata S, Enomoto T, Tsujimoto M, et al. Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms. Br J Cancer 2000;82:1446-52.
34. Ito Y, Monden M, Takeda T, et al. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br J Cancer 2000;82:1211-7.
35. Maher S, Toomey D, Condron C, Bouchier-Hayes D. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol Cell Biol 2002; 80:131-7.
36. Smith D, Sieg S, Kaplan D. Technical note: Aberrant detection of cell surface Fas ligand with anti-peptide antibodies. J Immunol 1998; 160:4159-60.
37. Strater J, Walczak H, Hasel C, et al. CD95 ligand (CD95L) immunohistochemistry: a critical study on 12 antibodies. Cell Death Differ 2001;8:273-8.
38. Lau HT, Stoeckert CJ. FasL-too much of a good thing? Transplanted grafts of pancreatic islet cells engineered to express Fas ligand are destroyed not protected by the immune system. Nat Med 1997;3: 727-8.
39. Rivoltini L, Radrizzani M, Accornero P, et al. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. J Immunol 1998;161:1220-30.